Aura's infrared light-activated drug stops tumor growth and preserves vision in eight eye cancer patients

Lei Lei Wu

News Reporter

Aura Biosciences said eight of 10 patients with a rare eye cancer who received a therapeutic dose of its experimental virus-like drug conjugate saw their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aura's infrared light-activated drug stops tumor growth and preserves vision in eight eye cancer patients

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Avid Bioservices to be sold to private equity firms for $1.1B

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Au­ra's in­frared light-ac­ti­vat­ed drug stops tu­mor growth and pre­serves vi­sion in eight eye can­cer pa­tients

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Aura's infrared light-activated drug stops tumor growth and preserves vision in eight eye cancer patients

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Avid Bioservices to be sold to private equity firms for $1.1B

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks